Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 6
Submit an article Journal homepage
178
Views
8
CrossRef citations to date
0
Altmetric
Drug Profile

Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia

Pierre Rofail Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA; Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA
,
Mariam Tadros Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA; Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA
,
Riham Ywakim Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA; Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA
,
Mina Tadrous Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Str., Toronto, ON, M5S 3M2, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Str., Toronto, ON, M5S 3M2, Canada
,
Allison Krug Principal, Artemis Biomedical Communications, LLC, WA, USA; Principal, Artemis Biomedical Communications, LLC, WA, USA
&
Leon E Cosler Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA; Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA. [email protected]
Pages 699-709 | Published online: 09 Jan 2014

References

  • Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J. Natl Compr. Cancer Netw. 3(4), 557–571 (2005).
  • Weycker D, Edelsberg J, Kartashov A, Barron R, Lyman G. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy 58(1), 8–18 (2012).
  • Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support. Care Cancer 18(5), 529–541 (2010).
  • Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors in the prevention for adverse effects in the therapeutic treatment of malignant lymphoma. Cochrane Database Syst. Rev. 4, CD003189 (2002).
  • Calhoun EA, Schumock GT, McKoy JM et al. Granulocyte colony–stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited. Pharmacoeconomics 23(8), 767–775 (2005).
  • Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin. Oncol. 30(4 Suppl. 13), 24–30 (2003).
  • Dale DC. Optimizing the management of chemotherapy-induced neutropenia. Clin. Adv. Hematol. Oncol. 1(11), 679–684 (2003).
  • Ozer H, Armitage JO, Bennett CL et al.; American Society of Clinical Oncology. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J. Clin. Oncol. 18(20), 3558–3585 (2000).
  • Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Engl. J. Med. 325(3), 164–170 (1991).
  • Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11(2), 172–179 (2008).
  • Maher DW, Lieschke GJ, Green M et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann. Intern. Med. 121(7), 492–501 (1994).
  • Hershman D, Neugut AI, Jacobson JS et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J. Natl Cancer Inst. 99(3), 196–205 (2007).
  • Lyman GH, Dale DC, Wolff DA et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J. Clin. Oncol. 28(17), 2914–2924 (2010).
  • Smith TJ, Hillner BE. Bending the cost curve in cancer care. N. Engl. J. Med. 364(21), 2060–2065 (2011).
  • Cosler LE, Calhoun EA, Agboola O, Lyman GH. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 24(4), 488–494 (2004).
  • Crawford J. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia. Oncology (Williston Park, NY) 20(5 Suppl. 4), 22–28 (2006).
  • Lyman GH. Risks and consequences of chemotherapy-induced neutropenia. Clin. Cornerstone 8(Suppl. 5), S12–S18 (2006).
  • Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J. Clin. Oncol. 25(21), 3158–3167 (2007).
  • Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr. Med. Res. Opin. 23(9), 2283–2295 (2007).
  • Griffiths RI, Barron RL, Gleeson ML et al. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. Pharmacoeconomics 30(2), 103–118 (2012).
  • Pérez Velasco R. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia. J. Oncol. Pharm. Pract. 17(3), 225–232 (2011).
  • Gruschkus SK, Lairson D, Dunn JK, Risser J, Du XL. Cost–effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin’s lymphoma patients treated with chemotherapy. Value Health 14(2), 253–262 (2011).
  • Sullivan SD, Ramsey SD, Blough DK, McDermott CL, Clarke L, McCune JS. Health care use and primary prophylaxis with colony-stimulating factors. Value Health 14(2), 247–252 (2011).
  • Zafar SY, Malin JL, Grambow SC et al.; for the Cancer Care Outcomes Research & Surveillance (CanCORS) Consortium. Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study. Cancer doi:10.1002/cncr.27815 (2012) (Epub ahead of print).
  • Biganzoli L, Untch M, Skacel T, Pico JL. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin. Oncol. 31(3 Suppl. 8), 27–34 (2004).
  • Zamboni WC. Pharmacokinetics of pegfilgrastim. Pharmacotherapy 23(8 Pt 2), 9S–14S (2003).
  • Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24(19), 3187–3205 (2006).
  • Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lympho proliferative disorders and solid tumors. Eur. J. Cancer 47(1), 8–32 (2011).
  • Crawford J, Althaus B, Armitage J et al.; National Comprehensive Cancer Network (NCCN). Myeloid growth factors. Clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 5(2), 188–202 (2007).
  • Dale D. Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Semin. Oncol. 30(4 Suppl. 13), 3–9 (2003).
  • Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10), 2258–2266 (2006).
  • Lyman GH, Lalla A, Barron RL, Dubois RW. Cost–effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin. Ther. 31(5), 1092–1104 (2009).
  • Fortner BV, Okon TA, Zhu L, Tauer K, Moore K, Templeton D. Human resource costs and patient time affected by the delivery of chemotherapy and neutropenia management. J. Clin. Oncol. 22, 14S (2004).
  • Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit. Rev. Oncol. Hematol. 50(2), 129–146 (2004).
  • Grigg AP. A comparison of pegfilgrastim and filgrastim. Clin. Adv. Hematol. Oncol. 3(3), 179–180 (2005).
  • Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl. Health Econ. Health Policy 7(3), 193–205 (2009).
  • Lyman G, Lalla A, Barron R, Dubois RW. Cost–effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States. Curr. Med. Res. Opin. 25(2), 401–411 (2009).
  • Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J. Manag. Care Pharm. 13(4), 337–348 (2007).
  • Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann. Pharmacother. 40(3), 402–407 (2006).
  • Weycker D, Malin J, Kim J et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin. Ther. 31(5), 1069–1081 (2009).
  • Kuderer NM, Lyman GH. Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J. Natl Cancer Inst. 103(12), 910–913 (2011).
  • Potosky AL, Malin JL, Kim B et al. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J. Natl Cancer Inst. 103(12), 979–982 (2011).
  • Potosky AL, Malin JL, Kim B, Chrischilles EA, Weeks JC. Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J. Natl Cancer Inst. 103(24), 1899–1901; author reply 1901 (2011).
  • Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin’s lymphoma treated with chemotherapy. J. Manag. Care Pharm. 9(Suppl. 2), 15–21 (2003).
  • Tan Sean P, Chouaid C, Hettler D, Baud M, Hejblum G, Tilleul P. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. Curr. Med. Res. Opin. 25(6), 1455–1460 (2009).
  • Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II–IV breast cancer. Oncol. Rep. 10(3), 715–724 (2003).
  • Heaney ML, Toy EL, Vekeman F et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer 115(20), 4839–4848 (2009).
  • Ozer H, Mirtsching B, Rader M et al. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 12(4), 484–494 (2007).
  • Teuffel O, Amir E, Alibhai S, Beyene J, Sung L. Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. Br. J. Cancer 104(9), 1377–1383 (2011).
  • Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J. Oncol. Pharm. Pract. 18(2), 171–179 (2012).
  • Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol. 7(Suppl. 1), 29–34 (2012).
  • Hirsch BR, Lyman GH. Biosimilars: are they ready for primetime in the United States? J. Natl Compr. Cancer Netw. 9(8), 934–942; quiz 943 (2011).
  • Zelenetz AD, Ahmed I, Braud EL et al. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J. Natl Compr. Cancer Netw. 9(Suppl. 4), S1–S22 (2011).
  • Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J. Clin. Oncol. 29(30), 3984–3989 (2011).
  • Talcott JA, Yeap BY, Clark JA et al. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J. Clin. Oncol. 29(30), 3977–3983 (2011).
  • Numnum TM, Kimball KJ, Rocconi RP, Kilgore LC, Straughn JM Jr. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma – a cost–effectiveness analysis. Int. J. Gynecol. Cancer 17(5), 1019–1024 (2007).
  • Danova M, Chiroli S, Rosti G, Doan QV. Cost–effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 95(2), 219–226 (2009).
  • Ramsey SD, Liu Z, Boer R et al. Cost–effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 12(2), 217–225 (2009).
  • Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr. Med. Res. Opin. 27(1), 79–86 (2011).
  • Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am. J. Clin. Oncol. 35(3), 267–274 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.